Invivyd, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Invivyd reported Q2 2026 PEMGARDA net product revenue of $14.3M (vs. $11.8M in Q2 2025, +21% growth). DECLARATION pivotal trial enrollment completed in June 2026 with top-line data expected late Q3 2026; LIBERTY Phase 3 trial fully dosed with late Q3 2026 data expected. Cash position of $160.1M as of June 30, 2026 expected to fund through DECLARATION readout. Critical setback: FDA issued 12-month advanced notice of PEMGARDA EUA termination in July 2026, effective June 29, 2027.
Why this rating
Revenue growth modest but near-term cash runway threatened by PEMGARDA EUA termination. VYD2311 pivotal data imminent—binary clinical outcome could materially reshape trajectory. Current $160.1M cash (3× market cap) funds operations through key milestone, but product pipeline dependency and regulatory uncertainty warrant elevated significance.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.